MicroRNA-126 Inhibits Proliferation and Metastasis in Prostate Cancer Via Regulation of ADAM9

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 May 29

PMID 29805636

Citations 20

Authors

Yibo Hua

Chao Liang

Chenkui Miao

Shangqian Wang

Shifeng Su

Pengfei Shao

Bianjiang Liu

Meiling Bao

Jundong Zhu

Aiming Xu

Jianzhong Zhang

Jie Li

Zengjun Wang

Affiliations

Soon will be listed here.

Abstract

The aberrant expression of microRNAs (miRs) has been identified to serve a crucial role in tumor progression. The present study aimed to evaluate the role of miR-126 in human prostate cancer (PCa). Firstly, miR-126 expression in prostate cancer tissues and cell lines was analyzed. A luciferase reporter assay and a rescue assay were performed, which identified ADAM metalloproteinase domain 9 (ADAM9) as the target gene of miR-126. Subsequently, Kaplan-Meier and log-rank analyses were used to investigate the association between ADAM9 expression and PCa prognosis. The results revealed that miR-126 expression was significantly downregulated in PCa tissues and cell lines. miR-126 overexpression was demonstrated to reduce PCa cell proliferation and metastasis, and to reverse the epithelial-mesenchymal transition process . In addition, as the target gene of miR-126, the upregulation of ADAM9 reestablished cell functions, including cell proliferation, migration and invasion. Patients with high ADAM9 expression levels exhibited a shorter biochemical recurrence-free survival time. In summary, miR-126 serves a role in the proliferation and metastasis of PCa cells, indicating that miR-126 and ADAM9 may represent potential biomarkers in the progression of advanced PCa, in addition to therapeutic targets.

Citing Articles

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.

Microglia-derived ADAM9 promote GHRH neurons pyroptosis by Mad2L2-JNK-caspase-1 pathway in subarachnoid hemorrhage.

Mao J, Bao Y, Liu F, Ye Q, Peng J, Nie J J Neuroinflammation. 2024; 21(1):302.

PMID: 39563331 PMC: 11575213. DOI: 10.1186/s12974-024-03299-x.

An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial-Mesenchymal Transition and Migration of Prostate Cancer Cell Lines.

Jotatsu Y, Sung S, Wu M, Takeda S, Hirata Y, Maeda K Int J Mol Sci. 2024; 25(12).

PMID: 38928352 PMC: 11203924. DOI: 10.3390/ijms25126646.

Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.

Ahmed K, Sheikh A, Fatima S, Ghulam T, Haider G, Abbas F Sci Rep. 2024; 14(1):10315.

PMID: 38705879 PMC: 11070424. DOI: 10.1038/s41598-024-60538-0.

MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications.

Hosseinpour-Soleimani F, Salmasi Z, Ghasemi Y, Tajbakhsh A, Savardashtaki A Heliyon. 2024; 10(7):e28167.

PMID: 38560206 PMC: 10979173. DOI: 10.1016/j.heliyon.2024.e28167.

References

Cui Y, Yamada S . N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin. PLoS One. 2013; 8(1):e55069. PMC: 3554680. DOI: 10.1371/journal.pone.0055069. View

Itabashi H, Maesawa C, Oikawa H, Kotani K, Sakurai E, Kato K . Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res. 2008; 38(6):601-13. DOI: 10.1111/j.1872-034X.2007.00304.x. View

Song L, Xie X, Yu S, Peng F, Peng L . MicroRNA‑126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer. Mol Med Rep. 2015; 13(2):1204-10. PMC: 4732865. DOI: 10.3892/mmr.2015.4661. View

Kopczynska E . Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel. Contemp Oncol (Pozn). 2016; 19(6):423-7. PMC: 4731449. DOI: 10.5114/wo.2015.56648. View

Josson S, Anderson C, Sung S, Johnstone P, Kubo H, Hsieh C . Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 2010; 71(3):232-40. PMC: 3174735. DOI: 10.1002/pros.21237. View

Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C . Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 2004; 131(1):41-8. DOI: 10.1007/s00432-004-0619-y. View

Hoang D, Iczkowski K, Kilari D, See W, Nevalainen M . Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2016; 8(2):3724-3745. PMC: 5356914. DOI: 10.18632/oncotarget.12554. View

Ebrahimi F, Gopalan V, Smith R, Lam A . miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2013; 96(1):98-107. DOI: 10.1016/j.yexmp.2013.12.004. View

Crawford M, Brawner E, Batte K, Yu L, Hunter M, Otterson G . MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373(4):607-12. DOI: 10.1016/j.bbrc.2008.06.090. View

10.

Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y . Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2005; 312(3):331-9. DOI: 10.1016/j.yexcr.2005.10.032. View

11.

Mahimkar R, Visaya O, Pollock A, Lovett D . The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J. 2004; 385(Pt 2):461-8. PMC: 1134717. DOI: 10.1042/BJ20041133. View

12.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

13.

Agostini M, Pucciarelli S, Calore F, Bedin C, Enzo M, Nitti D . miRNAs in colon and rectal cancer: A consensus for their true clinical value. Clin Chim Acta. 2010; 411(17-18):1181-6. DOI: 10.1016/j.cca.2010.05.002. View

14.

Yang J, Lan H, Huang X, Liu B, Tong Y . MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One. 2012; 7(8):e42978. PMC: 3416793. DOI: 10.1371/journal.pone.0042978. View

15.

Mazzocca A, Coppari R, De Franco R, Cho J, Libermann T, Pinzani M . A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005; 65(11):4728-38. DOI: 10.1158/0008-5472.CAN-04-4449. View

16.

Xie Y, Liu S, Lu W, Yang Q, Williams K, Binhazim A . Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol. 2014; 8(7):1355-64. PMC: 4198473. DOI: 10.1016/j.molonc.2014.05.006. View

17.

Kim J, Jeung H, Rha S, Yu E, Kim T, Shin Y . The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol Cancer Ther. 2014; 13(12):3074-85. PMC: 4258463. DOI: 10.1158/1535-7163.MCT-13-1001. View

18.

Duffy M, McKiernan E, ODonovan N, McGowan P . Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009; 15(4):1140-4. DOI: 10.1158/1078-0432.CCR-08-1585. View

19.

Kumar S, Davra V, Obr A, Geng K, Wood T, De Lorenzo M . Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. Oncoimmunology. 2018; 7(1):e1376155. PMC: 5739568. DOI: 10.1080/2162402X.2017.1376155. View

20.

Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat S . A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25(24):3576-81. DOI: 10.1200/JCO.2006.10.3820. View